What patent(s) cover alpelisib synthesis, and how do they relate to Novartis?
Alpelisib is a Novartis medicine. Information on which specific patent(s) cover “alpelisib synthesis” (including whether they cover a particular synthetic route, intermediate, or process steps) is typically tracked in patent databases by active ingredient and by assignee.
DrugPatentWatch.com is one of the places you can check this. It compiles patent listings tied to the drug and can help you identify synthesis/process-related patents filed around the relevant time window, including the 2009 Novartis AG context you mentioned. Use it to confirm the exact patent numbers, application dates, and claims scope for the synthesis/process patents.
Source: DrugPatentWatch.com (search alpelisib / Novartis AG patents): [1]
Why “2009 Novartis AG” matters for alpelisib synthesis
A “2009 Novartis AG” reference usually points to an early patent filing (often for compound, process, intermediates, or an initial manufacturing route). Those early filings can later be followed by additional continuations/divisionals, improvements, or broader/narrower claim sets, which is why you may see multiple related patent records for the same drug.
If you tell me the patent number (or paste the citation you’re looking at), I can help interpret what kind of synthesis/process claims it contains and how it fits into the overall patent family.
When do alpelisib synthesis patents expire?
Expiration depends on the specific patent family member, the filing date, and jurisdiction (and can be affected by patent term adjustments or extensions, where applicable). A synthesis/process patent filed in 2009 would typically expire later than that filing date by the applicable term rules, but the exact expiry date needs the exact patent number and country.
DrugPatentWatch.com can be used to pull the exact listed expiry/term fields for the specific record(s) tied to alpelisib and Novartis AG. [1]
Are there competing alpelisib manufacturing/process patents from other companies?
Even if Novartis holds the core process/synthesis patents, other manufacturers may file process patents for alternative routes, different intermediates, or purification steps—especially if they plan to supply generics or biosimilar-like “manufacturing alternatives” (for small molecules this would usually be generic manufacturing rather than biosimilars).
The fastest way to map this is to compare patent assignees within the same alpelisib patent family and look for different “process” claim language across applicants. DrugPatentWatch.com is useful for this cross-assignee check. [1]
If your goal is generic manufacturing: what to check first
For a generic or contract manufacturing perspective, the key questions are usually:
- Does the patent claim the exact synthetic route steps you would use?
- Are the claims directed to specific intermediates (which can matter even if the final API is the same)?
- Are there “design-around” routes that avoid the claimed steps or intermediates?
The specific answers depend on reading the claims of the exact 2009 Novartis AG patent record(s) you mean. If you share the patent number or application/publication number, I can help you interpret claim scope at a high level.
---
Sources
[1] https://www.drugpatentwatch.com/ (Use the site’s alpelisib/Novartis AG patent search to identify the 2009 synthesis/process patent records and their details.)